BioMarin's genetic disease therapy shows mixed results in late-stage study
18/05/2026 14:09
May 18 (Reuters) - BioMarin Pharmaceutical BMRN.O said on Monday its experimental treatment for a rare genetic condition met one of the two main goals in a late-stage study. (Reporting by Sneha S K; Editing by Shreya Biswas) ((Sneha.SK@thomsonreuters.com;))
Recent news on BioMarin Pharmaceutical
See all newsUS RESEARCH ROUNDUP-Analog Devices, IBM, Qualcomm
Brief: Biomarin Pharmaceutical Expects Q3 2026 Pre-Tax Charges Of $283 Million For Bought Ipr&D Expense
Brief: Biomarin Appoints Cara Bauer As Chief People Officer
Brief: Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026
U.S. STOCKS ON THE MOVE-GitLab, California utilities, Herbalife